Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Entrada Therapeutics (TRDA) Shares Outstanding (Diluted Average): 2022-2024

Historic Shares Outstanding (Diluted Average) for Entrada Therapeutics (TRDA) over the last 3 years, with Dec 2024 value amounting to $39.0 million.

  • Entrada Therapeutics' Shares Outstanding (Diluted Average) rose 2.05% to $41.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $41.5 million, marking a year-over-year increase of 2.05%. This contributed to the annual value of $39.0 million for FY2024, which is 18.01% up from last year.
  • As of FY2024, Entrada Therapeutics' Shares Outstanding (Diluted Average) stood at $39.0 million, which was up 18.01% from $33.1 million recorded in FY2023.
  • Entrada Therapeutics' Shares Outstanding (Diluted Average)'s 5-year high stood at $39.0 million during FY2024, with a 5-year trough of $31.3 million in FY2022.
  • In the last 3 years, Entrada Therapeutics' Shares Outstanding (Diluted Average) had a median value of $33.1 million in 2023 and averaged $34.4 million.
  • Data for Entrada Therapeutics' Shares Outstanding (Diluted Average) shows a peak YoY increased of 18.01% (in 2024) over the last 5 years.
  • Yearly analysis of 3 years shows Entrada Therapeutics' Shares Outstanding (Diluted Average) stood at $31.3 million in 2022, then increased by 5.61% to $33.1 million in 2023, then grew by 18.01% to $39.0 million in 2024.